Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Deoxyadenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.69 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.69 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.62 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.62 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.62 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.62 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.62 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | PNP | P00491 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | GAPDH | P04406 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyadenosine SCHEMBL431647 | 1.00 | HIF1A (0.70) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL193181 | 0.99 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL593935 | 0.99 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL5982291 | 0.99 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL532825 | 0.99 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL23982174 | 0.99 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL12222478 | 0.99 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL5182039 | 0.99 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL21637036 | 0.99 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL19877 | 0.99 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016168735-A1 | NUCLEOSIDE SUPPLEMENTATION TO PROMOTE CELLULAR FUNCTION, GENETIC STABILITY AND AUGMENT TRANSGENIC EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-20 | — | — | WO | claimed |
| US-12559797-B2 | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-24 | — | — | US | disclosed |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| US-12359000-B2 | Anti-8-hydroxy-2′-deoxyguanosine antibody or antibody fragment thereof, production method, kit, measuring method, and device for measurement | TDK CORPORATION (JP) | 2025-07-15 | — | — | US | disclosed |
| US-20250169516-A1 | METHODS, DEVICES AND COMPOSITIONS FOR PRESERVING HUMAN MILK | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| US-12239142-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20250037039-A1 | MOLECULAR DATA STORAGE USING COST-FREE MOLECULAR LIBRARIES | BROWN UNIVERSITY | 2025-01-30 | — | — | US | disclosed |
| US-20240318245-A1 | FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240268402-A1 | Methods, Devices and Compositions for Preserving Human Milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-08-15 | — | — | US | disclosed |
| US-12054768-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-06 | — | — | US | disclosed |
| US-6255290-B1 | REDUCING SENSITIVITY TO SKIN CANCER; TOPICAL ADMINISTERING OF NUCLEOTIDE | PRO-NEURON, INC. | 2001-07-03 | — | — | US | disclosed |
| WO-2001016149-A2 | 2-AZAPURINE COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-08 | — | — | WO | disclosed |
| US-6001611-A | OLIGONUCLEOTIDE PRIMER WITH NUCLEOTIDE TOWARDS THE 3' TERMINAL MODIFIED BY ADDITION OF GROUP ONTO EXOCYCLIC AMINE; RESULTS IN LESS NON-SPECIFIC PRODUCT, PARTICULARLY, PRIMER DIMER, AND A GREATER YIELD | ROCHE MOLECULAR SYSTEMS, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5783679-A | Purine nucleoside modifications by palladium catalyzed methods and oligonucleotides containing same | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-07-21 | — | — | US | disclosed |
| US-5672697-A | FORM OLIGONUCLEOTIDES STABLE TO NUCLEASE DEGRADATION | GILEAD SCIENCES, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5580972-A | DISPLACEMENT OF HALOGEN LEAVING GROUP ATTACHED TO PURINE RING WITH ORGANOTIN COMPOUND IN PRESENCE OF PALLADIUM CATALYST | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1996016972-A1 | PURINE NUCLEOSIDE MODIFICATIONS BY PALLADIUM CATALYZED METHODS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-06-06 | — | — | WO | disclosed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | LPL, CEL, LPO | PDE4D 855/4885PDE3A 1426/4885ADORA3 2755/4885 |
| US-12559797-B2 | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators | POLN, DNMT3A, POLRMT | PDE4D 818/4885PDE3A 2780/4885ADORA3 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.